Levemir Flexpen

Insulin detemir, the active ingredient in Levemir Flexpen, is a long‑acting insulin analog presented as a prefilled pen injection solution for subcutaneous use. It treats diabetes mellitus by providing basal insulin coverage in both type 1 and type 2 diabetes patients.

GNH USA supplies Levemir Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levemir Flexpen (insulin detemir) is used as basal insulin therapy in diabetes management.

- Type 1 diabetes mellitus: provides basal insulin to maintain glycemic control. - Type 2 diabetes mellitus: adds basal insulin when oral agents are insufficient. - Pediatric diabetes (age ≥2 years): supplies basal insulin for children with type 1 diabetes.

Levemir Flexpen may cause a range of adverse reactions.

Common Side Effects: - Hypoglycemia: low blood glucose levels, especially if meals are missed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase associated with improved glycemic control. - Lipodystrophy: localized changes in fat tissue at injection sites. - Edema: mild fluid retention, particularly in the lower extremities. - Headache: occasional mild to moderate headache.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Allergic reactions: rash, urticaria, or anaphylaxis. - Insulin antibody formation: may alter insulin effectiveness. - Lipohypertrophy: significant thickening of subcutaneous tissue. - Unexplained weight loss: may indicate inadequate insulin dosing.

When using Levemir Flexpen, consider the following precautions.

- Dose adjustment: titrate based on regular blood glucose monitoring. - Renal impairment: monitor closely as insulin clearance may be reduced. - Hepatic impairment: assess liver function and adjust dose if needed. - Pregnancy: use only if benefits outweigh potential risks. - Concomitant medications: avoid combining with other agents that increase hypoglycemia risk. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Flexpen can interact with several drug classes.

Major Interactions (Avoid): - Rapid‑acting insulin bolus without dose adjustment: may cause severe hypoglycemia. - Beta‑blockers: can mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely): - Sulfonylureas: increase risk of hypoglycemia. - Alcohol: potentiates hypoglycemic effect. - Thiazolidinediones: may exacerbate fluid retention. - ACE inhibitors: may enhance insulin sensitivity. - Corticosteroids: can raise blood glucose, requiring dose changes.